Evolving resistance landscape in gram-negative pathogens: An update on ß-lactam and ß-lactam-inhibitor treatment combinations for carbapenem-resistant organisms.
Pharmacotherapy
; 44(8): 658-674, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38949413
ABSTRACT
Antibiotic resistance has become a global threat as it is continuously growing due to the evolution of ß-lactamases diminishing the activity of classic ß-lactam (BL) antibiotics. Recent antibiotic discovery and development efforts have led to the availability of ß-lactamase inhibitors (BLIs) with activity against extended-spectrum ß-lactamases as well as Klebsiella pneumoniae carbapenemase (KPC)-producing carbapenem-resistant organisms (CRO). Nevertheless, there is still a lack of drugs that target metallo-ß-lactamases (MBL), which hydrolyze carbapenems efficiently, and oxacillinases (OXA) often present in carbapenem-resistant Acinetobacter baumannii. This review aims to provide a snapshot of microbiology, pharmacology, and clinical data for currently available BL/BLI treatment options as well as agents in late stage development for CRO harboring various ß-lactamases including MBL and OXA-enzymes.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Carbapenémicos
/
Beta-Lactamas
/
Inhibidores de beta-Lactamasas
/
Bacterias Gramnegativas
/
Antibacterianos
Límite:
Humans
Idioma:
En
Revista:
Pharmacotherapy
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Estados Unidos